Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15:2021:6651397.
doi: 10.1155/2021/6651397. eCollection 2021.

Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients

Xia Zhang  1 , Zhixian Wu  1 , Yonghai Peng  2 , Dongliang Li  1 , Yi Jiang  1 , Fan Pan  3 , Yi Li  4 , Yanhua Lai  5 , Zhongyuan Cui  1 , Kun Zhang  6
Affiliations

Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients

Xia Zhang et al. Biomed Res Int. .

Abstract

Background and aims: Patients with hepatocellular carcinoma (HCC) who undergo orthotopic liver transplantation (OLT) are at risk for posttransplant tumor recurrence. The aim of this study was to evaluate the correlation between the expression of Ki67, VEGF, and p53 in HCC and clinicopathological characteristics of HCC patients, as well as their predictive value for HCC recurrence after OLT.

Methods: 60 patients who underwent OLT and were found to have HCC in the liver explant. The expression of Ki67, VEGF, and p53 in HCC was detected by immunohistochemistry.

Results: Ki67 was associated with the tumor number and the grade of differentiation at baseline. VEGF was associated with the diameter and number of tumors, tumor differentiation, and lymph node metastasis. p53 was associated with the tumor diameter and tumor encapsulation. The expression of Ki67, VEGF, and p53 in HCC was correlated with the tumor recurrence after OLT, respectively. Among them, VEGF was an independent predictor for tumor recurrence after OLT.

Conclusion: Ki67, VEGF, and p53 are associated with the recurrence of HCC after OLT. VEGF independently predicts the recurrence of HCC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
(a) Positive immunostaining with nuclear Ki67 expression in HCC. (b) Negative Ki67 expression with low nuclear reactivity in HCC.
Figure 2
Figure 2
The positive expression rates of Ki67, VEGF, and p53 in the recurrence group and the control group.
Figure 3
Figure 3
(a) Positive immunostaining with VEGF expression in HCC. (b) Negative VEGF expression immunostaining in HCC.
Figure 4
Figure 4
(a) Positive immunostaining with p53 expression in HCC. (b) Negative p53 expression immunostaining in HCC.
Figure 5
Figure 5
(a) Disease-free survival (DFS) of patients with negative and positive expression of Ki67 expression; blue line: negative; light green line: positive; Log Rank P = 0.036; Breslow P = 0.047; (b) disease-free survival (DFS) of patients with negative and positive expression of VEGF. Blue line: negative; light green line: positive; Log Rank P = 0.003; Breslow P = 0.001. (c) Disease-free survival (DFS) of patients with negative and positive expression of p53, Log Rank P = 0.015; Breslow P = 0.011.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: a Cancer Journal for Clinicians. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Yang J. D., Roberts L. R. Hepatocellular carcinoma: a global view. Nature Reviews. Gastroenterology & Hepatology. 2010;7(8):448–458. doi: 10.1038/nrgastro.2010.100. - DOI - PMC - PubMed
    1. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516. - DOI - PubMed
    1. Parkin D. M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 2001;94(2):153–156. doi: 10.1002/ijc.1440. - DOI - PubMed
    1. Starzl T. E., Groth C. G., Brettschneider L., et al. Orthotopic homotransplantation of the human liver. Annals of Surgery. 1968;168(3):392–415. doi: 10.1097/00000658-196809000-00009. - DOI - PMC - PubMed

Substances